Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
Key takeaways
- On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon).
- At 80 weeks, participants on the 12 mg dose lost an average of 70.3 lbs (28.3%), with 45.3% losing 30% or more.
- Adverse events were consistent with incretin therapies, primarily causing nausea, diarrhea, constipation, and vomiting.
Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide Maham Fatima Sat, May 23, 2026 at 7:01 PM GMT+7 2 min read LLY Eli Lilly and Company (NYSE:LLY) is one of the best low risk stocks to buy in 2026. On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon). The 80-week study involved 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes. All doses met primary and secondary endpoints, showing significant weight loss and improvements in cardiometabolic markers like cholesterol and blood pressure.
At 80 weeks, participants on the 12 mg dose lost an average of 70.3 lbs (28.3%), with 45.3% losing 30% or more. A 104-week extension for those with a BMI ≥ 35 showed the 12 mg dose reached an average loss of 85.0 lbs (30.3%). The 9 mg and 4 mg doses yielded average 80-week weight losses of 25.9% and 19.0%, respectively.
Adverse events were consistent with incretin therapies, primarily causing nausea, diarrhea, constipation, and vomiting. Mild-to-moderate dysesthesia and urinary tract infections were also reported. Discontinuation rates due to side effects were 4.1% for 4 mg, 6.9% for 9 mg, and 11.3% for 12 mg, compared to 4.9% for the placebo.